The Wilmington, Del.-based company said it expects GAAP-based earnings per share to increase to $2.71 for fiscal 2016 as it enjoys a boost from the restructuring, more than offsetting a drag from negative currency exchange rates effects.
For the three months ended Sept. 30, DuPont, on an adjusted basis, earned 34 cents a share, ahead of analysts' forecasts of 21 cents.
Sales rose 1% to $4.92 billion, also beating Wall Street estimates.
The company attributed sales growth of 1% from a year earlier to a 3% volume increase, mainly in its performance materials, agriculture, nutrition and health, and industrial biosciences businesses. This was partly offset by a 2% drop in local prices, the company said.
DuPont is set to merge with Dow Chemical (DOW) - Get Report to create a company with a combined market cap of $130 billion. The merger is expected to deliver $3 billion in cost synergies and $1 billion upside from growth synergies, according to Dow.
"As a result of our continued performance and progress against strategic initiatives, we are raising our operating earnings guidance for the year," said CEO Ed Breen. "We also are making progress preparing for the merger with Dow. We developed an organizational design that fosters innovation and takes advantage of our market connections to drive growth. In addition, we have finalized plans to realize our cost synergies."